Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.82 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.82 |
| ▸ | SMC2 | O95347 | 1/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.82 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.82 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.82 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.82 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.82 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | NQO2 | P16083 | 1/20 | 0.69 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545993 | 0.93 | MAP2K1 (0.83) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL26937962 | 0.90 | MAP2K1 (0.85) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546010 | 0.90 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL21501424 | 0.90 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29555068 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL155456 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29353582 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546011 | 0.90 | MAP2K1 (0.79) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546013 | 0.90 | MAP2K1 (0.81) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546029 | 0.89 | MAP2K1 (0.91) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425637-B2 | mitogen-activated protein/extracellular signal-regulated (MAP/ERK)Kinase pathways; 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; hyperproliferative diseases; anticarcinogenic and antiinflammatory agent | ARRAY BIOPHARMA INC. (US) | 2008-09-16 | — | — | US | disclosed |